Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance

Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance

BackgroundRecent breakthroughs in cholangiocarcinoma (CCA) genomics have led to the discovery of many unique identifying mutations, of which HER2 has been found to be overexpressed specifically in cases of extrahepatic CCA. However, whether or not lapatinib (an oral tyrosine kinase inhibitor selecti...

Full description

Bibliographic Details
Main Authors: Zhiqing Bai, Zhiying Guo, Jiaxing Liu, Yu-Ann Chen, Qian Lu, Ping Zhang, Lili Hong, Yunfang Wang, Jiahong Dong
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Oncology
Subjects:
lapatinib
cholangiocarcinoma
HER2
ABCB1
gemcitabine
chemoresistance
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.860339/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.860339/full

Similar Items